Ankylosing Spondylitis: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

  • ID: 4418863
  • Drug Pipelines
  • 252 Pages
  • Datamonitor Healthcare
1 of 3

While the ankylosing spondylitis (AS) market will see downward pressure from the arrival of biosimilar versions of key anti-tumor necrosis factor (TNF) brands, increasing patient numbers and rising prices in the US will drive positive growth during 2014-23.

This report addresses the following questions:

  • Which agents do rheumatologists currently prescribe at first line?
  • Which are rheumatologists’ preferred anti-TNF biologics?
  • How will the availability of lower-cost biosimilars impact the sales and patient shares of the currently marketed biologics and the prospects of pipeline therapies?
  • What are rheumatologists’ views on Otezlaand what role can a novel oral small molecule play in the treatment of AS?
Note: Product cover images may vary from those shown
2 of 3

FORECAST: ANKYLOSING SPONDYLITIS
1. Executive Summary
2. Market Overview and Trends
3. Market Definition and Methodology
4. Cimzia (certolizumab)
5. Cosentyx (secukinumab)
6. Enbrel (etanercept)
7. Humira (adalimumab)
8. Remicade (infliximab)
9. Simponi (golimumab)
10. Primary Research Methodology

TREATMENT: ANKYLOSING SPONDYLITIS
11. Executive Summary
12. Primary Research Methodology
13. Disease Definition and Diagnosis
14. Country Treatment Trees
15. Current Treatment Options
16. Prescribing Trends
17. Compliance
18. Treatment Challenges and Unmet Needs
19. Pipeline Drugs and Future Treatments

EPIDEMIOLOGY: AXIAL SPONDYLOARTHRITIS IN THE US, JAPAN, AND 5EU
20. Executive Summary
21. Disease Background
22. Sources and Methodology
23. Forecast: Ankylosing Spondylitis
24. Forecast: Non-Radiographic Axial Spondyloarthritis
25. Forecast: Axial Spondyloarthritis
26. Epidemiologist Insight
27. Strengths and Limitations
28. Appendix: Additional Sources

MARKETED DRUGS: ANKYLOSING SPONDYLITIS
29. Executive Summary
30. Product Overview
31. Key Opinion Leader Research
32. Product profile: Cimzia
33. Product profile: Enbrel
34. Product profile: Humira
35. Product profile: Remicade
36. Product profile: Simponi

PIPELINE: ANKYLOSING SPONDYLITIS
37. Executive Summary
38. Clinical Pipeline Overview
39. Key Opinion Leader Research
40. Product profile (late stage): Cosentyx
41. Product profile (late stage): Otezla

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll